Kappa (k)- opioid ligands have received renewed attention due to their potential in the treatment of painful conditions, and their ability to attenuate the effects of psychostimulants (e.g., cocaine). The objective of these studies is to test the Central Hypothesis that dynorphin A(I-17) (an endogenous agonist at k-receptors), and E-2078 (a stable dynorphin A(1-8) analog), are high efficacy, peripherally selective agonists at the proposed """"""""k,"""""""" subtype opioid receptors, after systemic administration in rhesus monkeys. Several studies have focused on dynorphin pharmacology after central administration in rodents. In contrast, the effects of systemically administered dynorphins in monkeys have not been widely studied, and may be of particular clinical relevance, due to qualitative and quantitative similarities between k-receptor populations in non-human primates and humans. Studies to date reveal that systemically administered dynorphins produce some, but not all the effects commonly associated with non-peptidic k-agonists in primates, including humans. This is of particular interest, because clinical use of selective non-peptidic k-agonists has been limited by their undesirable effects (e.g., sedation and dysphoric subjective effects). The dynorphins may produce clinically relevant effects (e.g., anti-allodynia), with fewer or less severe undesirable effects. The agonist actions of intravenously administered dynorphin A(I-17) and E-2078 will therefore be characterized in assays ofthermal antinociception and capsaicin-induced thermal allodynia, and in a neuroendocrine endpoint, increases in serum prolactin levels. Prolactin levels can be used as a sensitive, quantitative marker of systemic dynorphin pharmacology in human and non-human primates. The receptor mediation of dynorphin effects in all the above assays will be initially studied by pretreatment with opioid antagonists (naltrexone and its peripherally selective analog, quaternary naltrexone). Overall, dynorphin A(I-I 7) and E-2078 will be compared to the non-opioid fragment, dynorphin A(2-17), to subtype-selective k-opioid ligands (U69,593 and bremazocine) and to a partial k-agonist (nalorphine). Specifically, we aim to determine whether the dynorphins'apparent efficacy, their proposed peripheral selectivity and their proposed k-subtype selectivity may be relevant to their in vivo profile in primates (and thus their clinical potential).

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA011113-06
Application #
6515586
Study Section
Special Emphasis Panel (ZRG1-IFCN-4 (01))
Program Officer
Lin, Yu
Project Start
1996-09-29
Project End
2005-02-28
Budget Start
2002-03-01
Budget End
2005-02-28
Support Year
6
Fiscal Year
2002
Total Cost
$334,759
Indirect Cost
Name
Rockefeller University
Department
Biology
Type
Other Domestic Higher Education
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Lovell, Kimberly M; Vasiljevik, Tamara; Araya, Juan J et al. (2012) Semisynthetic neoclerodanes as kappa opioid receptor probes. Bioorg Med Chem 20:3100-10
Kreek, M J; Schlussman, S D; Reed, B et al. (2009) Bidirectional translational research: Progress in understanding addictive diseases. Neuropharmacology 56 Suppl 1:32-43
Schmidt, Mark S; Prisinzano, Thomas E; Tidgewell, Kevin et al. (2005) Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci 818:221-5
Schmidt, Matthew D; Schmidt, Mark S; Butelman, Eduardo R et al. (2005) Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates. Synapse 58:208-10
Butelman, Eduardo R; Harris, Todd J; Kreek, Mary Jeanne (2004) Antiallodynic effects of loperamide and fentanyl against topical capsaicin-induced allodynia in unanesthetized primates. J Pharmacol Exp Ther 311:155-63
Butelman, Eduardo R; Ball, Jonathan W; Kreek, Mary-Jeanne (2004) Peripheral selectivity and apparent efficacy of dynorphins: comparison to non-peptidic kappa-opioid agonists in rhesus monkeys. Psychoneuroendocrinology 29:307-26
Butelman, Eduardo R; Harris, Todd J; Kreek, Mary Jeanne (2004) The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl) 172:220-4
Butelman, Eduardo R; Ball, Jonathan W; Harris, Todd J et al. (2003) Topical capsaicin-induced allodynia in unanesthetized primates: pharmacological modulation. J Pharmacol Exp Ther 306:1106-14
Butelman, Eduardo R; Ball, Jonathan W; Kreek, Mary-Jeanne (2002) Comparison of the discriminative and neuroendocrine effects of centrally penetrating kappa-opioid agonists in rhesus monkeys. Psychopharmacology (Berl) 164:115-20
Mathieu-Kia, A M; Kellogg, S H; Butelman, E R et al. (2002) Nicotine addiction: insights from recent animal studies. Psychopharmacology (Berl) 162:102-18

Showing the most recent 10 out of 14 publications